Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 1660 Tech Avenue, Unit 5 MISSISSAUGA ON L4W 5S7 |
Tel: | 1-877-7116055 |
Website: | https://covalon.com |
IR: | See website |
Key People | ||
Amir Boloor Executive Chairman of the Board | Brent Ashton Chief Executive Officer, Director | Katie Martinovich Interim Chief Financial Officer |
Ronald Hebert Senior Vice President - Marketing | Kim Crooks Senior Vice President - Operations | Jason F. Gorel Vice President - Finance |
Business Overview |
Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon's name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis. |
Financial Overview |
For the three months ended 31 December 2023, Covalon Technologies Ltd revenues decreased 25% to C$4.7M. Net loss increased from C$381K to C$852K. Revenues reflect Middle East segment decrease of 72% to C$379K, Rest of World segment decrease of 85% to C$136K, Middle East (Region) segment decrease of 72% to C$379K, Rest of World segment decrease of 85% to C$136K. |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $21.60M as of Dec 31, 2023 |
Annual revenue (TTM): | $25.07M as of Dec 31, 2023 |
EBITDA (TTM): | -$4.68M as of Dec 31, 2023 |
Net annual income (TTM): | -$4.93M as of Dec 31, 2023 |
Free cash flow (TTM): | -$3.82M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 24,669,577 as of Dec 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |